Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of TAR-200 with or without cetrelimab in BCG-unresponsive high-risk NMIBC
2020-002646-16Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine-releasing intravesical system and cetrelimab in transitional cell carcinoma of the bladder (TCC) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall complete response rate and Disease-free survival. Started Nov 2020; status: active.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2020-002646-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002646-16.